Mayank Mantani's questions to Mink Therapeutics Inc (INKT) leadership • Q2 2025
Question
Mayank Mantani of B. Riley Securities inquired about the trial design for the preventative Graft-versus-Host Disease (GVHD) study, including patient numbers and endpoints. He also asked for an update on the gastric cancer study and the company's plans for its targeted INKT program given its current cash position.
Answer
President and CEO Dr. Jennifer Buell explained that the Phase 1 GVHD trial will have a safety run-in followed by a 20-25 patient signal-seeking cohort at a target dose of one billion cells. For the gastric cancer program, she noted that mature follow-up data, including survival outcomes, is expected by year-end. Regarding the targeted INKT program, Dr. Buell stated that while the primary focus is on immune-mediated diseases, the engineered program has advanced significantly and can proceed to an IND with limited expense, potentially accelerated by a partnership.